Executive Summary
Keratoconjunctivitis sicca (Dry Eye) Global Clinical Trials Review, H2, 2016
Summary
GlobalData's clinical trial report, "Keratoconjunctivitis sicca (Dry Eye) Global Clinical Trials Review, H2, 2016" provides an overview of Keratoconjunctivitis sicca (Dry Eye) clinical trials scenario. This report provides top line data relating to the clinical trials on Keratoconjunctivitis sicca (Dry Eye). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global clinical trials landscape
Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
The Report provides enrollment trends for the past five years
Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
Assists in formulating key business strategies with regards to investment
Helps in identifying prominent locations for conducting clinical trials which saves time and cost
Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
Supports understanding of trials count and enrollment trends by country in global therapeutics market
Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Read More
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Keratoconjunctivitis sicca (Dry Eye) to Ophthalmology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Keratoconjunctivitis sicca (Dry Eye) to Ophthalmology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 307
Abbreviations 307
Definitions 307
Research Methodology 308
Secondary Research 308
About GlobalData 309
Contact Us 309
Disclaimer 309
Source 310
List of Figures
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Keratoconjunctivitis sicca (Dry Eye) to Ophthalmology Clinical Trials, G7 Countries (%), 2016* 14
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Keratoconjunctivitis sicca (Dry Eye) to Ophthalmology Clinical Trials, E7 Countries (%), 2016* 17
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 308
List of Tables
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Keratoconjunctivitis sicca (Dry Eye) to Ophthalmology Clinical Trials, G7 Countries (%), 2016* 14
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Keratoconjunctivitis sicca (Dry Eye) to Ophthalmology Clinical Trials, E7 Countries (%), 2016* 17
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Keratoconjunctivitis sicca (Dry Eye) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Keratoconjunctivitis sicca (Dry Eye) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Novartis AG, Allergan Plc, Santen Pharmaceutical Co Ltd, Valeant Pharmaceuticals International Inc, Otsuka Holdings Co Ltd, Innovative Medical Products Inc, Merck & Co Inc, Ora Inc, Pfizer Inc, Kissei Pharmaceutical Co Ltd
Keratoconjunctivitis sicca (Dry Eye) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Keratoconjunctivitis sicca (Dry Eye), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.
|
Agriculture and Animal Care
Automotive, Transportation and Warehousing
Banking Financial Services and Insurance
Consumer Products and Retail
Defense and Security
Education and Recruitment
Energy and Utilities
Food, Beverage and Tobacco
Healthcare
Manufacturing and Construction
Media and Entertainment
Metal, Mining and Chemicals
Public Sector and Administration
Technology and Telecom
